Which class of antibiotics primarily inhibits bacterial cell wall synthesis by targeting PBPs?

Get ready for the Manor Preboards Module 3 Test. Enhance your skills with diverse multiple choice questions, detailed explanations, and insights. Ensure exam success!

Multiple Choice

Which class of antibiotics primarily inhibits bacterial cell wall synthesis by targeting PBPs?

Explanation:
Bacteria rely on a sturdy cell wall made of peptidoglycan, and penicillin-binding proteins carry out the final cross-linking that gives that wall its strength. Beta-lactam antibiotics mimic the normal substrate of these enzymes and bind to their active sites, irreversibly blocking transpeptidase activity. Without proper cross-linking, the wall weakens as the bacteria grow, and the cell bursts from osmotic pressure. Other major antibiotic classes don’t target the cell wall: macrolides inhibit protein synthesis by binding the 50S ribosome, fluoroquinolones disrupt DNA replication by inhibiting gyrase/topoisomerase, and tetracyclines block tRNA binding to the 30S ribosome. Because of this direct interference with cell wall construction, beta-lactams are the class that primarily inhibits bacterial cell wall synthesis by targeting PBPs.

Bacteria rely on a sturdy cell wall made of peptidoglycan, and penicillin-binding proteins carry out the final cross-linking that gives that wall its strength. Beta-lactam antibiotics mimic the normal substrate of these enzymes and bind to their active sites, irreversibly blocking transpeptidase activity. Without proper cross-linking, the wall weakens as the bacteria grow, and the cell bursts from osmotic pressure. Other major antibiotic classes don’t target the cell wall: macrolides inhibit protein synthesis by binding the 50S ribosome, fluoroquinolones disrupt DNA replication by inhibiting gyrase/topoisomerase, and tetracyclines block tRNA binding to the 30S ribosome. Because of this direct interference with cell wall construction, beta-lactams are the class that primarily inhibits bacterial cell wall synthesis by targeting PBPs.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy